Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020

2020-07-30
Price :
Published : Jul-2020
No. of Pages : 56

Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020

Summary

The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas.

Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.

Scope

– Profiles of the most promising treatments and vaccines in the pipeline for COVID-19, including SWOT analyses, an overview of trials, and summaries of available data
– An overview of the clinical trials landscape, including discussion of the approaches being adopted for therapeutic and vaccine development
– Highlights in deal-making trends, particularly public-private partnerships
– Proprietary expert insights on COVID-19 R&D obtained by GlobalData’s investigative journalism team
– Analysis of the impact of the outbreak on clinical trial timelines across disease areas and geographies
– Assessment of regulatory delays associated with the pandemic
– GlobalData poll results on topics covered in the report

Reasons to Buy

– Stay abreast of COVID-19 R&D

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – July 2020

Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - July 2020 Summary GlobalData's "Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals - July 2020" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Addit......
$1000

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria meningitidis Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Oropharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oropharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical tr......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy